Identification of Dipeptidyl Peptidase IV Inhibitors: Virtual Screening, Synthesis and Biological Evaluation

Inhibition of dipeptidyl peptidase IV is an important approach for the treatment of type‐2 diabetes. In this study, we reported a multistage virtual screening workflow that integrated 3D pharmacophore models, structural consensus docking, and molecular mechanics/generalized Born surface area binding energy calculation to identify novel dipeptidyl peptidase IV inhibitors. After screening our in‐house database, two hit compounds, HWL‐405 and HWL‐892, having persistent high performance in all stages of virtual screening were identified. These two hit compounds together with several analogs were synthesized and evaluated for in vitro inhibition of dipeptidyl peptidase IV. The experimental data indicated that most designed compounds exhibited significant dipeptidyl peptidase IV inhibitory activity. Among them, compounds 35f displayed the greatest potency against dipeptidyl peptidase IV in vitro with the IC50 value of 78 nm. In an oral glucose tolerance test in normal male Kunming mice, compound 35f reduced blood glucose excursion in a dose‐dependent manner.

[1]  E. Sugaru,et al.  Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability. , 2015, Bioorganic & medicinal chemistry.

[2]  Duane D. Miller,et al.  Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif , 2014, The FEBS journal.

[3]  Yueqing Gu,et al.  Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors , 2013, PloS one.

[4]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[5]  S. Genheden,et al.  Comparison of MM/GBSA calculations based on explicit and implicit solvent simulations. , 2013, Physical chemistry chemical physics : PCCP.

[6]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[7]  Douglas R. Houston,et al.  Consensus Docking: Improving the Reliability of Docking in a Virtual Screening Context , 2013, J. Chem. Inf. Model..

[8]  H. Fujii,et al.  Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[9]  Tomonori Kobayashi,et al.  Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. , 2012, Bioorganic & medicinal chemistry.

[10]  H. Utsumi,et al.  Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2012, Bioorganic & medicinal chemistry.

[11]  Hongjian Xu,et al.  Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. , 2012, European journal of medicinal chemistry.

[12]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[13]  Hyeong-Seok Lim,et al.  Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. , 2012, Clinical therapeutics.

[14]  Gretchen A. Stevens,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[15]  Ye-Hwang Cheong,et al.  Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. , 2011, Bioorganic & medicinal chemistry letters.

[16]  P. Lu,et al.  Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes. , 2011, Bioorganic & medicinal chemistry letters.

[17]  Dariusz Plewczynski,et al.  VoteDock: Consensus docking method for prediction of protein–ligand interactions , 2011, J. Comput. Chem..

[18]  J. Yano,et al.  Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor. , 2011, Journal of medicinal chemistry.

[19]  E. Sugaru,et al.  Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. , 2010, Bioorganic & medicinal chemistry letters.

[20]  J. Holst,et al.  Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes , 2010, Expert opinion on investigational drugs.

[21]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[22]  C. Bailey,et al.  Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. , 2008, Frontiers in bioscience : a journal and virtual library.

[23]  W. Metzler,et al.  Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation , 2008, Protein science : a publication of the Protein Society.

[24]  G. Scapin,et al.  Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. , 2008, Journal of medicinal chemistry.

[25]  G. Scapin,et al.  Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[26]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[27]  S. Dejager,et al.  Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes , 2007, Diabetologia.

[28]  R. Pratley,et al.  Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes , 2007, Current medical research and opinion.

[29]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[30]  P. Bates,et al.  Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. , 2006, Drugs of today.

[31]  P. Flatt,et al.  Function of a long‐term, GLP‐1‐treated, insulin‐secreting cell line is improved by preventing DPP IV‐mediated degradation of GLP‐1 , 2005, Diabetes, obesity & metabolism.

[32]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[33]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[34]  A. Weber.  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[35]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[36]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[37]  T. Hughes,et al.  1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2002, Journal of medicinal chemistry.

[38]  Jong Young Joung,et al.  Identification of Novel Rab27a/Melanophilin Blockers by Pharmacophore-Based Virtual Screening , 2013, Applied Biochemistry and Biotechnology.

[39]  J. Yano,et al.  Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. , 2011, Bioorganic & medicinal chemistry.

[40]  P. Willett,et al.  PHARMACOPHORE PERCEPTION , DEVELOPMENT , AND USE IN DRUG DESIGN , 2011 .

[41]  T. Kurtz,et al.  Type 2 diabetes and oral antihyperglycemic drugs. , 2008, Current medicinal chemistry.

[42]  G. Scapin,et al.  (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2007, Bioorganic & medicinal chemistry letters.

[43]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.